8-K: AXIM Biotechnologies Announces Change of Control, New President and Director Following Death of CEO

AXIM Biotechnologies experienced a change of control with the transfer of Series C Preferred Stock, appointed a new President, Catalina Valencia, and a new Series C Director, also Catalina Valencia, following the death of former President and CEO John W. Huemoeller II.

Summary

• AXIM Biotechnologies has undergone a change of control due to the transfer of its Series C Preferred Stock from Juniper & Ivy Corporation to Medical Marijuana, Inc. and then to Kettner Investments, LLC.
• This transfer occurred as settlement of a $515,000 promissory note and the waiver of $1,090,000 in convertible note defaults and $66,000 in accrued interest.
• Kettner Investments, now holding the Series C Preferred Stock, has the right to appoint a majority of the board of directors.
• Robert Malasek, AXIM's CFO, is a member and Chairman of Kettner's Executive Committee.
• Catalina Valencia was appointed as the new President of AXIM Biotechnologies on October 9, 2024, due to the illness of the previous President and CEO, John W. Huemoeller II.
• John W. Huemoeller II passed away on October 12, 2024.
• Catalina Valencia was also appointed as a Series C Director on October 14, 2024, filling the vacancy left by Mr. Huemoeller's death.
• Ms. Valencia has extensive experience in biotechnology, telecommunications, and hi-tech industries, including a history with AXIM through the acquisition of Sapphire Biotech.

Sentiment

Score: 5

Explanation: The document contains both positive and negative elements. The appointment of a new president and director is positive, but the death of the former CEO and the change of control introduce uncertainty. The use of equity to settle debts is a concern.

Positives

• The appointment of Catalina Valencia brings a seasoned executive with extensive experience in biotechnology and related fields.
• The resolution of the promissory note and convertible note defaults through the transfer of Series C Preferred Stock simplifies the company's financial structure.
• The new leadership may bring fresh perspectives and strategies to the company.

Negatives

• The death of the former President and CEO, John W. Huemoeller II, is a significant loss for the company.
• The change of control introduces uncertainty regarding the future direction of the company.
• The transfer of Series C Preferred Stock was used to settle debts, which may indicate financial challenges.

Risks

• The change in control could lead to shifts in company strategy and operations.
• The new leadership may face challenges in maintaining the company's momentum.
• The company's financial situation may be precarious given the use of equity to settle debts.

Future Outlook

The document does not provide specific forward-looking statements, but the change in leadership and control suggests a potential shift in the company's future direction.

Management Comments

• The board of directors appointed Catalina Valencia as the new President due to the illness of John W. Huemoeller II.
• Juniper appointed Catalina Valencia to fill the Series C Director vacancy following the death of John W. Huemoeller II.

Industry Context

The biotechnology industry is characterized by high levels of innovation and risk, and leadership changes can significantly impact a company's trajectory. The change of control and new leadership at AXIM could lead to a shift in strategic direction and product development.

Comparison to Industry Standards

• Changes in control are not uncommon in the biotechnology sector, especially for companies in early stages of development or facing financial challenges.
• The appointment of a new president and director with a strong background in biotechnology is a common practice to bring in expertise and leadership.
• The use of equity to settle debts is a common practice for companies with limited cash flow, but it can also signal financial distress.

Management Changes

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the change of control and leadership.
• Employees may experience uncertainty due to the change in leadership.
• Customers and partners may be impacted by any changes in the company's strategy.

Next Steps

• The new board of directors will likely set the strategic direction for the company.
• The company will need to integrate the new leadership team.
• The company will need to address any financial challenges.

Key Dates

Keywords

change of control, Series C Preferred Stock, board of directors, Catalina Valencia, John W. Huemoeller II, Kettner Investments, biotechnology, executive appointment, corporate governance